http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2583597-C1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3190be5d4946a766d6e44b377544cbbb
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-007
filingDate 2015-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2016-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8686fcf6831924d1cc7e5aa997e4da48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69c9fa1f6b3278c864994f8fcc0cfae3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90d02eb23ccf4bd9ef13ec7b4ccf813c
publicationDate 2016-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2583597-C1
titleOfInvention Method for surgical treatment of macular rupture of complicated retinal detachment
abstract FIELD: medicine. n SUBSTANCE: invention refers to medicine, namely, to ophthalmology, and can be used for surgical treatment of macular rupture complicated by amphiblestrodes detachment. After the vitrectomy and removal of posterior hyaloid membrane PFOC is introduced into the cavity of a vitreous body to the equator, then in 2.0-2.5 mm to inferotemporal arcade from the rupture edge an ILM end is separated from from the amphiblestrodes with capturing the ILM edge; membrane is separated throughout 2-3 hour meridians, by a motion directed along the arc of an imaginary circle with the macular rupture in the centre while seeing to it that the amphiblestrodes area at a distance of 1.0-1.2 mm from the rupture edge is intact; during the next stage one recaptures ILM separated along the arc in the end point and by movement along the radius separates ILM stopping at 0.5-0.8 mm to the rupture edge; then another recapturing is performed at the end point and ILM is separated throughout 2-3 hour meridians in the opposite direction while seeing to it that amphiblestrodes area at a distance of 0.5-0.8 mm from the rupture edge is intact; separation of the given ILM area is completed by a movement directed radially to get into the initial point; in the specified manner one gradually performs peeling of ILM areas, while around the macular rupture there is formed a ILM foveolar fragment surrounded by amphiblestrodes zone without ILM in the form of an open ring; the last ILM area is removed so as to avoid closing of the ring at a distance equal to 2.5-3.0 diameters of the macular rupture, thus leaving an ILM flap in the zone of ILM peeling; the remaining ILM flap is separated in the direction from the outer border to the centre stopping 0.5-0.8 mm from the rupture edge, then one applies to the macular rupture the obtained ex tempore patient's blood serum, after which the ILM flap is turned over and placed on the macular rupture, closing it; the flap is slightly squeezed from above by a vitretom; then one replaces liquid by air, performs draining retinotomy; after expiry of sub-amphiblestrodes liquid PFOC is replaced by air and in the air medium silicone oil is introduced into the vireal cavity. n EFFECT: invention ensures reduced intra-operative injuries, complete anatomical attachment of amphiblestrodes and closing of the macular rupture, improving or preserving visual functions and reducing a risk of recurrent amphiblestrodes detachment. n 1 cl
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2754515-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2730933-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2715989-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2688395-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2770114-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2708150-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2722987-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2754805-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2685648-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2803007-C1
priorityDate 2015-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2254105-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2367391-C1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419526573
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID74483

Total number of triples: 27.